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Abstract
Background: Bone marrow stromal cell antigen 2 (BST-2) is a cellular factor that restricts the egress of viruses such
as human immunodeficiency virus (HIV-1) from the surface of infected cells, preventing infection of new cells. BST-
2 is variably expressed in most cell types, and its expression is enhanced by cytokines such as type I interferon
alpha (IFN-a). In this present study, we used the beta-retrovirus, mouse mammary tumor virus (MMTV) as a model
to examine the role of mouse BST-2 in host infection in vivo.
Results: By using RNA interference, we show that loss of BST-2 enhances MMTV replication in cultured mammary
tumor cells and in vivo. In cultured cells, BST-2 inhibits virus accumulation in the culture medium, and co-localizes
at the cell surface with virus structural proteins. Furthermore, both scanning electron micrograph (SEM) and
transmission electron micrograph (TEM) show that MMTV accumulates on the surface of IFNa-stimulated cells.
Conclusions: Our data provide evidence that BST-2 restricts MMTV release from naturally infected cells and that
BST-2 is an antiviral factor in vivo.
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Background
Bone marrow stromal cell antigen 2 (BST-2) protein
also known as tetherin/CD317 is a potent restriction
factor against a wide range of enveloped viruses such as
HIV, FIV, KSHV, MMTV, SIV, Lassa, Marbug, Ebola,
and MLV [1-5]. BST-2 achieves its anti-viral effect by
connecting both viral and host cell membranes, thus
preventing virus egress [6-9]. While BST-2 inhibits virus
release, most viruses including HIV-1, HIV-2, and Ebola
virus have developed strategies to antagonize BST-2 by
degradation, down-regulation of expression, or reduction
of its steady-state level [1,2,7,10-14]. In addition to inhi-
b i t i n gv i r u se g r e s sa n dv i r u sr eplication in cell culture,
there is evidence that, following interferon-induction,
BST-2 is up-regulated and incorporated into budding
virions [2,6,8,9]. While the antiviral activity of BST-2
has been demonstrated in tissue culture cells, there has
been no evidence that BST-2 exerts antiviral activity in
vivo. In this context, we evaluated the ability of mouse
BST-2 to restrict the replication of the exogenous mur-
ine retrovirus mouse mammary tumor virus (MMTV) in
cell culture and in mice.
In vivo, MMTV first infects antigen presenting cells
(APCs) such as B cells and dendritic cells (DCs) at the
site of infection [15-19]. MMTV infected APCs present
virus-encoded superantigen (Sag) to T cells expressing
Sag-specific T-cell receptor (TCR) Vb chains. This
immunological synapse causes stimulation of Sag-reac-
tive T cells and proliferation of lymphocytes thereby
promoting virus replication. Both lymphoid and myeloid
c e l l si n f e c t e dw i t hM M T Va r ec a p a b l eo fp r o d u c i n g
infectious virus [19] and infected lymphoid cells are
necessary for virus spread and mammary carcinogenesis
[20,21].
Although MMTV infects and causes mammary cancer
in infected mice; nonetheless, infected cells do not pro-
duce high virus titer, and time to MMTV-induced can-
cer is rather long, suggesting that virus replication and
s p r e a dm a yb er e s t r i c t e db yh o s tf a c t o r sl i k eB S T - 2 .
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MMTV Gag and Env, and inhibits MMTV particle
release in tissue culture cells. Importantly, MMTV infec-
tion of mice was significantly inhibited by BST-2.
Results
IFNa induces BST-2 expression and restricts MMTV
release
BST-2 expression results in retention of a wide range of
virus-like particles (VLPs) assembled in tissue culture
[1-4], and IFNa or IFNg treatment induces the transcrip-
tion of the gene encoding BST-2 [1,22]. We hypothesized
that IFNa induction of BST-2 in an MMTV producing
cell line would enhance BST-2 expression and suppress
MMTV release to the culture medium. We treated
MMTV-producing GR cells with IFNa or vehicle and
then measured BST-2 mRNA and surface protein levels,
as well as extra- and intra- cellular viral particles. We
observed a significant increase in BST-2 mRNA (Figure
1A) and protein (Figure 1B) levels upon IFNa treatment.
This increase in BST-2 levels was accompanied by a
reduction in the accumulation of MMTV particles in the
culture supernatant, with no change in intracellular viral
load as assessed by viral RNA (Figures 1C and 1D) and
viral protein (Figure 1E). Additionally, the reduction in
particle accumulation in culture supernatant results in
lower viral load when such supernatants were used to
infect MMTV susceptible cells (Figure 1F). This data
demonstrate that IFNa induces endogenous BST-2 in
MMTV infected cells and suggest that BST-2 may be the
critical factor limiting the accumulation of MMTV parti-
cles in the culture supernatant.
Next, we examined whether BST-2 is responsible for
IFNa-dependent inhibition of MMTV release. GR cells
stably silenced for BST-2 expression with a lentiviral con-
struct carrying BST-2 specific shRNA or control shRNA
were stimulated with IFNa or vehicle. Culture superna-
tants were collected 24 hours later and subjected to Wes-
tern blot analysis for MMTV capsid protein p27. The
corresponding cells were examined for BST-2 protein (Fig-
ure 1G). Results show that while shRNA was able to
silence BST-2 and enhance accumulation of viral particles
in culture supernatant (Figure 1H), IFNa stimulation of
shRNA cells results in increased cell surface BST-2 protein
expression (Figure 1G) and a reduction in the amount of
viral particles accumulated in the culture supernatant (Fig-
ure 1H). This result shows that the reduction in the
amount of extracellular viral particles observed in IFNa
treated cells is linked to BST-2 induction.
IFNa causes accumulation of MMTV structures at the cell
surface
In IFNa treated cells, less MMTV particles were
detected in the culture supernatant without apparent
defect in accumulation of intracellular viral components
(Figures 1E, 1H). As BST-2 was shown to block the
release of various enveloped viruses/VLPs from the cells
[1,23], we hypothesize that exposure of MMTV-produ-
cing GR cells to IFNa will result in accumulation of
MMTV virions on the cell surface. To test this, GR cells
were stimulated with IFNa or vehicle and 24 hours
later, cells were processed for scanning electron micro-
scopy (SEM). In vehicle treated GR cells, 100 nm sized
buds were readily observed (Figure 2A). The buds were
commonly found on the tip of filamentous structures
projecting from the cells surface. IFNa induction drasti-
cally increased the number of bud-containing filaments
(Figure 2B). To confirm that the buds were indeed vir-
ions, thin sections of GR cells prepared under the same
treatment conditions were analyzed with transmission
electron microscope (TEM). Electron dense virion struc-
tures, about 100 nm in diameter (black arrowheads),
were detected at the cells surface (Figure 2C and 2D).
As expected, in IFNa treated cells, particles that are
linked to each other were also observed (Figure 2D).
The TEM thus validated that the filamentous structures
observed with SEM contain virion(s). Together the elec-
tron microscopy data strongly suggest that exposure of
MMTV infected cells to IFNa results in retention of
MMTV virions on the cell surface.
BST-2 co-localizes with MMTV structural proteins at the
cell surface
Consistent with its role in tethering virus particles to the
surface of the infected cell, BST-2 has been shown to co-
localize with structural proteins of other retroviruses
along the plasma membrane of cells [1,3]. To examine
whether BST-2 co-localizes with MMTV structural pro-
teins, BST-2, rat glucocorticoid receptor (RSVGR), and
MMTV proviral genome (HP) were co-transfected into
293T cells. Two days later, cells were processed and
immuno fluorescently stained to detect BST-2 and
MMTV structural proteins. Results show partial co-loca-
lization of MMTV Env (Figure 3A) or Gag (Figure 3B)
with BST-2 at the cell surface. Our data support previous
demonstrations of co-localization of BST-2 with HIV-1
Env in infected cells [24] and co-localization of SIV Env
and BST-2 in activated primary rhesus macaque lympho-
cytes infected with SIV [25]. In addition, our data are in
line with previous report of BST-2 co-localization with
the Gag proteins of other retro- and filo-viruses [3].
Depletion of endogenous BST-2 enhances MMTV particle
release and replication in cell culture
To test the hypothesis that BST-2 is responsible for inhibi-
tion of MMTV release, we used an RNAi assay to deter-
mine whether silencing of endogenous BST-2 expression
would lead to higher MMTV particle release and higher
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Page 2 of 12Figure 1 IFNa-dependent induction of endogenous BST-2 restricts MMTV release. GR cells were treated with 1000 units of endotoxin free
recombinant IFNa or PBS for 24 hours. Virus was purified from culture supernatants and the corresponding cell extracts were harvested. (A) Cell
extracts were used to determine level of BST-2 mRNA by qPCR, presented as fold change in BST-2 mRNA relative to vehicle treated cells; (B) and
surface BST-2 by flow cytometry with the peak on the left as the isotype antibody control. Culture supernatants and their corresponding cell
extracts were used to evaluate level of viral RNA, (C) extracellular viral RNA, (D) intracellular viral RNA, (E) and viral protein detected by antibody
to MMTV capsid protein p27. Tubulin is a loading control. Data are presented as fold change in vRNA relative to vehicle treated samples. (F)
Culture supernatants from IFNa or vehicle treated GR cells were used to infect TRH3 cells. Twenty four hours after infection, cells were harvested
and used for DNA extraction followed by qPCR analysis of viral DNA normalized to GAPDH. Data are presented as fold change in viral DNA of
cells infected with supernatants from IFNa treated cells relative to viral DNA of cells infected with supernatants from vehicle treated cells. Error
bars are standard deviation, and p is the significance level, ns is not significant. Experiments were performed at least three times with similar
results. (G) GR cells were stably transduced with shRNA targeting mouse BST-2 gene (shRNA) or a non-targeting shRNA (shControl). Cells were
treated with IFNa (1000 units/ml) or vehicle. Twenty four hours later a portion of cells were used for FACS analysis of surface BST-2 level. (H)
Culture supernatant and the remaining cells were examined for level of extracellular and intracellular viral proteins by Western blot.
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control siRNA, or a siRNA that targets BST-2 mRNA (Fig-
ure 4A). Silencing endogenous BST-2 with siRNA (Figure
4B: upper panel - mRNA, lower panel - protein) enhanced
extracellular viral RNA and protein yield compared to
cells treated with control siRNA (Figure 4C and 4D
respectively), suggesting that endogenous BST-2 affects
MMTV particle release. Similar results were obtained
when endogenous BST-2 was silenced in GR cells with
lentivirus-based shRNA targeting mouse BST-2 (Figures
4E,F,G). Given the ability of endogenous BST-2 to regulate
MMTV release, we wondered if BST-2 expression could
affect replication and spread of MMTV. Hence, we
depleted BST-2 with siRNA in mammary epithelial
NMuMG cells (Figure 4H: left panel -mRNA, right panel -
protein) and in 3T3 MEFs (Figure 4I: left panel - mRNA,
right panel - protein). To evaluate the effect of reduced
BST-2 levels on MMTV replication, we infected siRNA
treated cells with MMTV, and observed significant differ-
ences in viral spread over a course of 96 hours in both
NMuMG (Figure 4H: bottom panel) and 3T3 MEFs (Fig-
ure 4I: bottom panel). These data suggest that BST-2
impairs MMTV replication and spread in epithelial and
fibroblast cells.
Overexpression of BST-2 inhibits MMTV replication
To confirm our finding that BST-2 restricts MMTV
replication in cultured cells, we transiently expressed
varying amounts of BST-2 or empty vector in TRH3
(293T cells that stably express MMTV entry receptor
transferrin receptor 1). Twenty four hours later, a por-
tion of cells were examined for BST-2 expression
Figure 2 Retention of MMTV virions on the cells surface of IFNa treated cells. GR cells were treated with vehicle (left panels) or IFNa (right
panels) for 24 hours and then processed for scanning (A and B) or transmission (C and D) electron microscopy. MMTV virions with a distinct
capsid and fuzzy appearing envelope are indicated with black arrowheads (C and D). Each panel has indicated scale bar. Cyt is cytoplasm.
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Page 4 of 12(Figure 5A), and the remaining cells were infected with
MMTV. DNA was extracted from infected cells and
used for qPCR examination of virus load 24 hours after
infection. Results show that while cells transfected with
BST-2 plasmid show lower levels of MMTV DNA
across board, transfection of 100 ng of BST-2 plasmid
results in about 60% lower infection (Figure 5B), indicat-
ing that BST-2 restricts MMTV replication in a dose
dependent manner. Whether lower infection observed in
BST-2 transfected cells is a result of cells being infected
at low multiplicity or lower number of cells being
infected is unclear. To address this question, we first
generated TRH3 cells stably expressing BST-2 or empty
vector (Figure 5C) and infected cells with MMTV.gfp
purified from MMTV-producer cell line, CGRES6.
These cells produce virions derived from a molecular
clone of MMTV (pGR102ES) with a gfp gene inserted
into its long terminal repeat (LTR) [26]. Infected cells
were collected 24 and 96 hours later and examined for
level and intensity of gfp expression. Results show that
both at 24 and 96 hours after infection, level of gfp
expression was significantly lower in BST-2 expressing
cells compared to cells expressing empty vector control
(Figure 5D). In addition, gfp mean fluorescence intensity
(MFI) was also lower in cells expressing BST-2 at both
time points (Figure 5E). These results suggest that BST-
2 potently restricts MMTV replication as evidenced by
the larger proportion of cells infected in the absence of
BST-2 (Figure 5D, solid blue line and solid red line)
compared to lower number of cells infected in the pre-
sence of BST-2 (Figure 5D, broken blue line and broken
red line).
BST-2 specific siRNA depleted endogenous BST-2 in
murine lymph nodes
We have demonstrated that loss of BST-2 in tissue cul-
ture cells enhances MMTV replication and spread (Fig-
ures 4H and 4I lower panels). To examine the role of
Figure 3 MMTV Gag co-localizes with BST-2. 293T cells transiently transfected with BST-2 and MMTV proviral constructs were permeabilized,
fixed, stained, and analyzed with confocal microscopy for BST-2 and (A) MMTV Env or (B) MMTV Gag localization. Green is MMTV Env or Gag,
red is BST-2, orange is merge. Phase contrast shows cell morphology. Areas of BST-2/Env or BST-2/Gag co-localization at the cells surface are
highlighted in white rectangular boxes and magnified by 2.5X. Experiments were repeated at least three times with similar results.
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Page 5 of 12BST-2 in virus infection in vivo, we first determined
whether MMTV target cells and tissues such as dendri-
tic cells (DCs), macrophages (MFs), lymph nodes and
spleens from different mouse strains (C3H/HeN and
C57BL/6) that express BST-2 mRNA. We used the
mammary epithelial cell line, NMuMG as a reference
and show that BST-2 transcript is present in all MMTV
targets (Figure 6A). BST-2 mRNA is higher in bone
marrow derived DC (BMDC) compared to bone marrow
derived macrophages (BMMF), popliteal lymph nodes
and the spleen, with a modest difference in BST-2 levels
between C3H/HeN and C57BL/6 mice. Since lymph
nodes express BST-2, we examined whether BST-2 spe-
cific siRNA is capable of silencing BST-2 in vivo.F o l -
lowing inoculation of mice with siRNA or siControl
subcutaneously in the hind footpad, we evaluated the
Figure 4 Depletion of endogenous BST-2 enhances MMTV particle release and virus replication in tissue culture cells. GR cells were
transfected with siRNA targeting the mouse BST-2 gene or non-targeting control siRNA (siControl). At 24 or 72 hours after transfection, both
culture supernatants and their corresponding cells were collected. Virions were purified from supernatants, and both virions and corresponding
cells were used for RNA and protein extractions. Aliquots of the supernatants were used to quantify the amount of extracellular virus. (A)
Location of the siRNA sequence on the BST-2 gene; (B) Level of BST-2 following siRNA treatment (upper panel, bars- BST-2 mRNA presented as
fold change relative to the control and lower panel, histogram- BST-2 protein); (C) Level of extracellular viral RNA following treatment with BST-2
siRNA and siControl, presented as fold change relative to the control; (D) Western blot of extracellular and intracellular viral proteins detected by
antibody to the capsid protein p27; tubulin is loading control. Next, GR cells were stably transduced with shRNA targeting mouse BST-2 mRNA
or a non-targeting shRNA. (E) Cells were used to determine extent of BST-2 knockdown by qPCR. (F and G) Culture supernatants and their
corresponding cells were used to examine level of (F) extracellular and intracellular viral proteins by Western blot, stable integration of lentiviral
particles carrying shRNA was evaluated by puromycin PCR; (G) extracellular viral RNA. To evaluate the effect of BST-2 on MMTV replication,
NMuMG cells or 3T3 MEF cells were transfected with siRNA or siControl. Twenty four hours after transfection, cells were infected with MMTV and
harvested at different times (shown on the figures) for DNA extraction and qPCR analysis of viral DNA, (H) qPCR analysis of endogenous NMuMG
BST-2 mRNA (top-left panel), cell surface expression (top-right panel), MMTV DNA (bottom-left panel); (I) qPCR analysis of endogenous 3T3 MEF
BST-2 mRNA (top-left panel), cell surface expression (top-right panel), MMTV DNA (bottom-left panel) following knockdown with siRNA or
siControl. Data are normalized to GAPDH and presented as fold change relative to siControl treated cells. Error bars are standard deviation, p is
significance level. Experiments were repeated at least three different times with similar results.
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hours, siRNA significantly depleted lymph node BST-2
mRNA to about 7 fold (Figure 6B) with a modest reduc-
tion in protein level (Figure 6C: upper and lower), and
no effect on BST-2 levels of mice inoculated with
siControl or no siRNA. We also examined the expres-
sion of IFNa,I F N b,a n d2 ’-5’-oligoadenylate synthetase
(OAS) transcripts, and observ e dt h a tm i c et r e a t e dw i t h
siRNA sequences have similar levels of IFNa,I F N b, and
OAS transcripts despite reduced BST-2 mRNA level
Figure 5 Ectopic expression of BST-2 inhibits MMTV replication in tissue culture cells. (A-B) Varying concentrations of BST-2 were
transiently transfected into TRH3 cells. Twenty four hours later, (A) a portion of cells were processed for FACS analysis and evaluated for BST-2
surface expression and (B) the remaining portion was infected with MMTV and examined for level of infection by qPCR 24 hours after infection.
Data are normalized to GAPDH and presented as fold change in viral DNA relative to viral DNA of vector transfected cells. (C-E) Constructs of
BST-2 and puromycin were stably co-expressed in TRH3 cells. Twenty four hours later, fresh medium containing puromycin drug was added to
cells to facilitate the selection of transfectants. After about 10 days in selection, individual colonies of transfected cells were picked and amplified.
A portion of cells were examined for (C) BST-2 surface expression by FACS. Another portion of cells were infected with MMTV-gfp. Twenty four
and ninety six hours after infection, cells were analyzed for infection as determined by (D) level of gfp expression or (E) intensity of gfp
expression using FACS. Error bars are standard deviation, p is significance level. All experiments were repeated at least three different times with
similar results.
Jones et al. Retrovirology 2012, 9:10
http://www.retrovirology.com/content/9/1/10
Page 7 of 12(Additional file 1). These data suggest that BST-2 speci-
fic siRNA reduced BST-2 expression in vivo without eli-
citing IFN response.
siRNA mediated silencing of endogenous BST-2 enhances
MMTV replication and spread in vivo
Local administration of BST-2 siRNA mediates BST-2
depletion in vivo (Figures 6B and 6C). To determine the
role of endogenous BST-2 in virus replication in vivo,
we administered either a control siRNA, or siRNA that
targets BST-2 mRNA to mice, followed by infection
with MMTV. Virus replication was significantly higher
in siRNA treated mice compared to their siControl or
no siRNA counterparts (Figure 6D). In addition, we
observed significantly higher virus load in the spleens of
mice that received siRNA (Figure 6E). These data show
for the first time that siRNA is capable of mediating
BST-2 knock down in vivo (Figures 6B and 6C); and
Figure 6 In vivo replication of MMTV is enhanced in the absence of BST-2. (A) Naïve female age-matched C3H/HeN (n = 3) and C57BL/6 (n
= 3) were profiled for BST-2 expression by qPCR analysis of BST-2 mRNA levels in popliteal lymph node, spleen, bone marrow derived DCs
(BMDC), and bone marrow derived macrophages (BMMF). Data are presented as fold change in BST-2 level relative to NMuMG BST-2. (B-E)
Naïve age-matched C3H/HeN mice were inoculated with siRNA (n = 5), siControl (n = 5), or PBS (No siRNA, (n = 5) subcutaneously on the hind
foot pad. Forty-eight hours after inoculation, mice were infected with MMTV on the same footpad. Cells of the draining popliteal lymph nodes
(B-D) or spleen (E) were used for DNA and total RNA extraction or flow cytometry. (B) qPCR analysis of BST-2 mRNA 48 hours after siRNA
inoculation, presented as fold change in BST-2 level relative to siControl treated mice (C) Flow cytometric analysis of surface BST-2 following in
vivo siRNA treatment showing scatter plot of the gated cell population (upper panels) and % of BST-2 expressing cells (lower panel). Inset in the
lower panel is mean florescence intensity - MFI. (D) qPCR analysis of proviral DNA in the popliteal lymph node of infected mice, presented as
fold change in viral DNA relative to viral DNA in siControl lymph node at 24 hours after infection. (E) qPCR analysis of proviral DNA in the spleen
of infected mice, presented as fold change in viral DNA relative to viral DNA in siControl spleen at 24 hours after infection. Error bars are
standard deviation, p is significance level. All experiments were performed with either 3 or 5 mice per group and repeated at least three times
with similar results.
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site of initial infection results in higher rate of virus
replication and dissemination in vivo (Figures 6D and
6E).
Discussion
Here, we describe an important anti-viral function for
BST-2 in the mouse. Many in vitro and ex vivo studies
have shown that BST-2 inhibits the replication of a
number of viruses [1-9]. By using MMTV, we directly
demonstrate that BST-2 plays a role in virus replication
in vivo. Administration of siRNA sequences into mouse
footpad results in knock-down of endogenous lymph
n o d eB S T - 2 .T h i sa s s a ya l l o w e du st od e m o n s t r a t et h a t
BST-2 functions as a virus restriction factor in a natural
host organism. We chose to silence lymph node BST-2
because lymphocytes play a critical role in the in vivo
infection with MMTV and other retroviruses such as
HIV-1; and in the absence of a knockout model, siRNA
provides the best alternative. The significantly higher
virus load observed in BST-2 silenced lymph nodes
implies that loss of BST-2 enhances virus replication.
BST-2 expression inhibits the egress of HIV-1, HIV-2,
Ebola, Marburg and MLV; and we found that it also
inhibits the accumulation of MMTV particles in the cul-
ture medium. The inhibitory effect of BST-2 on accu-
mulation of extracellular MMTV particles in culture
supernatant is consistent with the effect of BST-2 on
virus release from the cell surface as has been observed
for other viruses [1-5]. The observation that BST-2 co-
localizes with MMTV Env and Gag further suggests that
BST-2 prevents the accumulation of MMTV particles in
culture supernatants. Our EM data support previously
documented studies that MMTV buds off from the
plasma membrane and microvilli [27]. The cell surface
visualization by SEM provides an opportunity to demon-
strate that induction of BST-2 with IFNa facilitates
accumulation of MMTV on the cell surface. This find-
ing was backed by our protein analyses showing that sti-
mulation of MMTV producer cells with IFNa results in
less accumulation of MMTV particles in the culture
supernatant.
Conclusion
We have directly demonstrated in this study that loss of
BST-2 enhances replication of MMTV in vivo. However,
it remains to be determined why mice become infected
with MMTV in the presence of the endogenous BST-2.
It is worth noting that MMTV has co-existed with mice
for over 20 million years [28] and perhaps must have
evolved to avoid most hosts’ anti-viral defense mechan-
isms. The findings of this study are important as it has
shown that BST-2 function as anti-viral in the host.
Based on this report, we are now focused on using
MMTV as a model to understand the role of BST-2 in
viral pathogenesis.
Materials and methods
Ethics statement
All experiments involving mice were performed in
accordance to NIH guidelines, the Animal Welfare Act,
and US federal law. The experiments approved by the
University of Iowa Animal Care and Use Committee
(IACUC). Mice were housed according to the policies of
the Institutional Animal Care and Use Committee of
the University of Iowa.
Molecular constructs
BST-2 plasmids used in the study were previously
described [4] and kindly provided by Dr. Paul Bates,
University of Pennsylvania, Philadelphia, PA. The
MMTV env (Q61) construct [20], MMTV molecular
clone HYB PRO (HP) [29], and the rat glucocorticoid
receptor (RSVGR) [30] were kindly provided by Dr.
Susan Ross, University of Pennsylvania, Philadelphia, PA.
Animals
C57BL/6 and C3H/HeN mice were purchased from the
Jackson Laboratory and National Cancer Institute (NCI)
respectively.
Cell lines
NMuMG (derived from normal mammary tissue of a
Namru mouse strain), GR (a mammary carcinoma cell
line), Mm5MT (a mammary carcinoma cell line from
C3H/HeN mouse strain), 3T3 MEF and 293T cell lines
were purchased from American Type Culture Collection
(ATCC). TRH3 cells are 293T-mTfR1 (293T cells that
stably express MMTV entry receptor transferrin recep-
tor 1 [mTfr1]) and have been previously described [31].
TRH3-BST-2 and TRH3-Vector cells (TRH3 cells stably
expressing BST-2 or empty vector). CGRES6-GFP cells
(feline kidney stably transfected with a GFP-tagged
MMTV proviral construct [26] was obtained from Dr.
Susan Ross of the university of Pennsylvania. All cells
were maintained according to the suppliers’ instructions.
Both GR and Mm5MT cells are from MMTV-induced
mammary tumor and both produce infectious MMTV
particles.
Generation of TRH3 cell-line stably expressing mBST-2
To generate a TRH3-BST2 stable cell line, we co-trans-
fected 6 μg of BST-2 and 1 μg of puromycin (selection
marker) plasmids into TRH3 cells using polyethyleni-
mine (PEI) transfection reagent. Following overnight
incubation, transfection medium was changed, and
replaced with medium containing puromycin dihy-
drochloride (3 μg/ml, Santa Cruz Biotechnology, Inc.).
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medium to remove dead cells. By day 10 after transfec-
tion, several individual clones of stably transfected cells
emerged and clones were picked and expanded. Level of
BST-2 expression was examined by FACs analysis. After
examination, clones with the highest BST-2 expression
were expanded and some cells frozen or used for
experiments.
Antibodies, siRNAs, shRNAs, and other reagents
Antibodies used in this study includes goat anti-gp52
(Env) and anti-p27 (capsid) previously described [32,33].
Others are unconjugated rat anti-mouse BST-2 clone
129c, Alexa flour 647 conjugated anti-mouse BST-2 clone
129c [34], and FITC conjugated anti-mouse BST-2 clone
927 purchased from eBioscience. Rabbit anti-BST-2 and
mouse anti-tubulin were from Abnova and Li-core respec-
tively. The following isotype control antibodies were used:
Rat IgG2a and Rat IgG2b, both from eBiosciences. The
following secondary antibodies from Li-core were used:
RDye 680 donkey anti-mouse, IRDye 680 LT conjugated
donkey anti-rabbit, IRDye 800CW donkey anti-goat, and
IRDye 800CW conjugated goat anti-rabbit. Rabbit anti-rat
Alexa Fluor 594 and chicken anti-goat Alexa Fluor 488
were from Invitrogen. The in vivo ready silencer Select tar-
get specific siRNA, control siRNA, and SiPort NeoFX
transfection reagent were from Ambion while plasmids for
target-specific Mission shRNA, control shRNA, and poly-
brene were obtained from Sigma. BST-2 shRNA and con-
trol shRNA lentiviral particles were produced from
plasmids of target-specific Mission shRNA and control
shRNA by the University of Iowa Vector Core Facility.
Recombinant mouse interferon alpha (IFN-a)w a sf r o m
Miltenyi Biotech. Vector-shield was from Vector Labora-
tories and Lipofectamine 2000 was from Invitrogen.
Infection of mice
In vivo infection of mice was performed with 50 μlo f
MMTV.MM5MT inoculated subcutaneously on the
hind footpad. At different times after infection, mice
were sacrificed and the popliteal lymph node draining
the site of infection from each mouse was harvested.
Lymphocytes were obtained and used for fluorescence-
activated cell-sorting (FACS) analysis or used for DNA
and RNA extraction.
BST-2 knockdown by shRNA and siRNA in cell culture
BST-2 shRNA lentiviral particles containing 3 target-
specific constructs and shRNA constructs encoding a
scrambled sequence (Santa Cruz Biotechnology, Santa
Cruz, CA) or target specific Mission shRNA and a cor-
responding control shRNA (Sigma) were used to knock
down BST-2 gene expression. Briefly, mouse mammary
epithelial tumor cell line GR were transduced with
control or BST-2 shRNA lentiviral particles at a ratio of
5 infectious units of virus per cell in the presence of 8
μg/mL polybrene. The next day, fresh media was added
to cells and incubated for another 24 hours. In some
experiments, puromycin at 2 μg/ml was added to the
culture medium for the selection of cells that had stably
incorporated shRNA. BST-2 gene silencing was con-
firmed at the mRNA and protein levels by qPCR and
FACS. Knockdown of BST-2 by siRNA was achieved
using Ambion’s in vivo ready silencer Select target speci-
fic or siRNA in vivo ready scrambled siRNA. Briefly, 250
pico moles of siRNA sequences were mixed with Lipo-
fectamine 2000 following manufacturer’s recommenda-
tion and used to transfect NMuMG, GR or MEFs. The
next day, fresh medium was added to cells and incu-
bated until assayed for BST-2 and MMTV mRNA.
NMuMG and MEFs were passaged and used for detec-
tion of BST-2 and virus replication experiments. Experi-
ments were repeated at least 3 times with similar results.
Western blots
Western blots of virus preparations, cell lysates from
MMTV infected cells, cells transiently transfected with
env and capsid plasmids, or immuno-precipitates of pro-
tein complexes were probed with anti-total MMTV,
anti-gp52, and anti-p27. The species-appropriate IRDye
secondary antibodies were used, followed by detection
with the Odyssey Infrared Imaging System (LI-COR
Biosciences).
DNA, RNA isolation and real-time quantitative PCR (qPCR)
DNA or total RNA was isolated from cells, tissues, and
mice lymphocytes using the QIAGEN-QIAamp DNA
Mini Kit or RNeasy Mini Kit (Qiagen, Inc.) respectively
according to manufacturer’s instructions. For cDNA
synthesis, equivalent amounts of RNA treated with
DNase I (Qiagen, Inc.) were reverse-transcribed with
high capacity cDNA reverse transcription Kit (Applied
Biosystems, ABI), and the cDNA was amplified with pri-
mers specific to BST-2, MMTV.Mm5MT, IFNa,I F N b,
2’-5’-OAS, and GAPDH. DNA was used to quantita-
tively detect integrated proviruses [32,33], using primers
specific to the MMTV long terminal repeats and puro-
mycin. Semi-quantitative PCR was performed using Ver-
iti 96-Well Thermal Cycler, and real time qPCR was
carried out using ABI 7500 FAST thermal cycler (ABI).
All amplifications were normalized to GAPDH and data
are presented as fold change relative WT or naïve sam-
ple depending on experiment. Sequence of primer pairs
used is available (Table 1).
Immuno-fluorescence and confocal microscopy
293T cells were co-transfected with plasmids expressing
BST-2, rat glucocorticoid receptor (RSVGR) and
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The next day cells were treated with DEX and 24 hours
later fixed in 4% paraformaldehyde in PBS for 10 min-
utes. Cells were then washed once with PBS and incu-
bated for 3 hours in IF buffer (0.5% Triton X-100, 0.5%,
sodium deoxycholate, 1% bovine serum albumin, 0.05%
sodium azide in PSB). Primary antibodies were diluted
in IF buffer as follows: rat anti-BST-2 (1:100), goat anti-
p27 (1:100) or goat anti-gp52 (1:100) and detected with
rabbit anti-rat Alexa Fluor 594 and chicken anti-goat
Alexa Fluor 488. All secondary autobodies were dilated
1:1000 in IF buffer. All confocal microscopy images
were taken with Zeiss 510 confocal microscope.
Flow cytometry
Approximately, 1 × 10
6 GR, MM5MT, NMuMG, 3T3
MEF, 293T, and lymphocytes were stained in PBS +
1% bovine serum albumin (Sigma-Aldrich) for 30 min
on ice with Alexa flour 647 anti-mouse BST-2 (clone
129c) or FITC anti-mouse BST-2 (clone 927) and APC
anti-mouse IgG2b. Cells were extensively washed in
PBS, fixed with 2% paraformaldehyde and subjected to
FACS. At least ten-thousand events were collected for
each sample using FACS calibur flow cytometer (BD).
Cellular frequency and mean fluorescence intensity
(MFI) were determined by Flowjo analysis software
(TreeStar).
Virus release assay
GR cells were induced for virus production with 1 μM
of dexamethasone (DEX) [35] and treated with IFNa or
vehicle for 24 hours. Culture supernatants from cells
were clarified by low speed centrifugation, passed
through a 0.45 μmf i l t e r ,a n dv i r i o n sw e r ep e l l e t e d
through a 20% sucrose layer at 32,000g as previously
described (30-31). Pellets of virus particles and corre-
sponding cell extracts were denatured and analyzed by
SDS-PAGE and Western blot assays. In some experi-
ments, virus particles were used for qPCR analysis of
viral RNA or to infect TRH3 cells.
Statistical analysis
Statistical analysis of significant differences between
experimental groups was tested using paired two-tailed
Student’s t test, and a p value of 0.05 was considered
significant. Error bars represent standard deviations.
Additional material
Additional file 1: BST-2 siRNA did not elicit interferon response in
mice. Age-matched C3H/HeN mice were inoculated with siRNA (n = 3),
siControl (n = 3), or PBS (WT, (n = 3) subcutaneously on the hind foot
pad. Forty-eight hours after inoculation, mice were sacrificed and cells of
the draining popliteal lymph node used for total RNA extraction.
Quantitative PCR was used to examine mRNA levels of (A) BST-2 (B)
IFNa, (C) IFNb, and (D) 2’-5’-oligoadenylate synthetase (OAS). Data is
presented as fold change relative to WT mice. Error bars are standard
deviation, and p is significance level. Experiments were performed with 3
mice per group and repeated at least three times with similar results.
List of abbreviations
BST-2: bone marrow stromal cell antigen 2; HIV-1: human immunodeficiency
virus type 1; HIV-2: human immunodeficiency virus type 2; IFNα: interferon
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OAS: oligoadenylate synthetase; NMuMG: normal murine mammary gland;
SIV: simian immunodeficiency virus; SEM: scanning electron micrograph;
TEM: transmission electron micrograph.
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Table 1 Primer sequences
Primer name Forward sequence Reverse sequence
mBST-2 TCAGGAGTCCCTGGAGAAGA ATGGAGCTGCCAGAGTTCAC
MMTV CGTGAAAGACTCGCCAGAGCTA TAATGTTCTATTAGTCCAGCCACTGT [32,33]
a
GAPDH CCCCTTCATTGACCTCAACTACA CGCTCCTGGAGGATGGTGAT [32,33]
a
Puromycin CGTACGCACCCTCGCCGC TCGTCCGCGACCCACACC
IFNa GCTAGGCTCTGTGCTTTCCTGATG CTCAGGTACACAGTGATCCTGTGG
IFNb AACAGGTGGATCCTCCACGCTGCG GTGGAGAGCAGTTGAGGACATCTCC
2’-5’-OAS CTTTGATGTCCTGGGTCATGT CTCCGTGAAGCAGGTAGAG
Sequence of primer pairs used in this study. Citation means the primer has been previously reported.
Jones et al. Retrovirology 2012, 9:10
http://www.retrovirology.com/content/9/1/10
Page 11 of 12Received: 20 October 2011 Accepted: 27 January 2012
Published: 27 January 2012
References
1. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is
antagonized by HIV-1 Vpu. Nature 2008, 451:425-30.
2. Goffinet C, Schmidt S, Kern C, Oberbremer L, Keppler OT: Endogenous
CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in
rodent cells and is resistant to antagonists from primate viruses. J Virol
2010, 84:11374-84.
3. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M,
Hatziioannou T, Bieniasz PD: Broad-spectrum inhibition of retroviral and
filoviral particle release by tetherin. J Virol 2009, 83:1837-44.
4. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P: Tetherin-mediated
restriction of filovirus budding is antagonized by the Ebola glycoprotein.
Proc Natl Acad Sci USA 2009, 106:2886-91.
5. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J,
Cannon PM: Ebola virus glycoprotein counteracts BST-2/Tetherin
restriction in a sequence-independent manner that does not require
tetherin surface removal. J Virol 2010, 84:7243-55.
6. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA,
Johnson MC, Bieniasz PD: Tetherin inhibits HIV-1 release by directly
tethering virions to cells. Cell 2009, 139:499-511.
7. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S,
Andrew A, Strebel K, Krausslich HG: CD317/tetherin is enriched in the HIV-
1 envelope and downregulated from the plasma membrane upon virus
infection. J Virol 2010, 84:4646-58.
8. Hammonds J, Wang JJ, Yi H, Spearman P: Immunoelectron microscopic
evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions
and the plasma membrane. PLoS Pathog 2010, 6:e1000749.
9. Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J: Direct
restriction of virus release and incorporation of the interferon-induced
protein BST-2 into HIV-1 particles. PLoS Pathog 2010, 6:e1000701.
10. Le Tortorec A, Neil SJ: Antagonism to and intracellular sequestration of
human tetherin by the human immunodeficiency virus type 2 envelope
glycoprotein. J Virol 2009, 83:11966-78.
11. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, Cohen EA:
Suppression of Tetherin-restricting activity upon human
immunodeficiency virus type 1 particle release correlates with
localization of Vpu in the trans-Golgi network. J Virol 2009, 83:4574-90.
12. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT:
Antagonism of CD317 restriction of human immunodeficiency virus type
1 (HIV-1) particle release and depletion of CD317 are separable activities
of HIV-1 Vpu. J Virol 2010, 84:4089-94.
13. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC,
Cannon PM: HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by
sequestration in a perinuclear compartment. Retrovirology 2010, 7:51.
14. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P,
Towers GJ, Neil SJ: The RING-CH ligase K5 antagonizes restriction of
KSHV and HIV-1 particle release by mediating ubiquitin-dependent
endosomal degradation of tetherin. PLoS Pathog 2010, 6:e1000843.
15. Burzyn D, Rassa JC, Kim D, Nepomnaschy I, Ross SR, Piazzon I: Toll-like
receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol
2004, 78:576-84.
16. Beutner U, Kraus E, Kitamura D, Rajewsky K, Huber BT: B cells are essential
for murine mammary tumor virus transmission, but not for presentation
of endogenous superantigens. J Exp Med 1994, 179:1457-66.
17. Martin P, Ruiz SR, del Hoyo GM, Anjuere F, Vargas HH, Lopez-Bravo M,
Ardavin C: Dramatic increase in lymph node dendritic cell number
during infection by the mouse mammary tumor virus occurs by a
CD62L-dependent blood-borne DC recruitment. Blood 2002, 99:1282-8.
18. Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR: Critical role of
dendritic cells in mouse mammary tumor virus in vivo infection. J Virol
2007, 81:3769-77.
19. Dzuris JL, Golovkina TV, Ross SR: Both T and B cells shed infectious mouse
mammary tumor virus. J Virol 1997, 71:6044-8.
20. Golovkina TV, Dudley JP, Ross SR: B and T cells are required for mouse
mammary tumor virus spread within the mammary gland. J Immunol
1998, 161:2375-82.
21. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR: APOBEC3
proteins made in mammary epithelial cells can be packaged into
retroviruses and restrict transmission of milk-borne virions. Cell Host
Microbe 2010, 8:534-43.
22. Yoo H, Park SH, Ye SK, Kim M: IFN-gamma-induced BST2 mediates
monocyte adhesion to human endothelial cells. Cell Immunol 2011,
267:23-9.
23. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC,
Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T: Nef proteins from
simian immunodeficiency viruses are tetherin antagonists. Cell Host
Microbe 2009, 6:54-67.
24. Jolly C, Booth NJ, Neil SJ: Cell-cell spread of human immunodeficiency
virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J
Virol 2010, 84:12185-99.
25. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT: Compensatory
changes in the cytoplasmic tail of gp41 confer resistance to tetherin/
BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 2011, 9:46-57.
26. Indik S, Gunzburg WH, Salmons B, Rouault F: Mouse mammary tumor
virus infects human cells. Cancer Res 2005, 65:6651-9.
27. Gonda MA, Arthur LO, Zeve VH, Fine DL, Nagashima K: Surface localization
of virus production on a glucocorticoid-stimulated oncornavirus-
producing mouse mammary tumor cell line by scanning electron
microscopy. Cancer Res 1976, 36:1084-93.
28. Bittner JJ: SOME POSSIBLE EFFECTS OF NURSING ON THE MAMMARY
GLAND TUMOR INCIDENCE IN MICE. Science 1936, 84:162.
29. Shackleford GM, Varmus HE: Construction of a clonable, infectious, and
tumorigenic mouse mammary tumor virus provirus and a derivative
genetic vector. Proc Natl Acad Sci USA 1988, 85:9655-9.
30. Miesfeld R, Rusconi S, Godowski PJ, Maler BA, Okret S, Wikstrom AC,
Gustafsson JA, Yamamoto KR: Genetic complementation of a
glucocorticoid receptor deficiency by expression of cloned receptor
cDNA. Cell 1986, 46:389-99.
31. Zhang Y, Rassa JC, deObaldia ME, Albritton LM, Ross SR: Identification of
the receptor binding domain of the mouse mammary tumor virus
envelope protein. J Virol 2003, 77:10468-78.
32. Okeoma CM, Lovsin N, Peterlin BM, Ross SR: APOBEC3 inhibits mouse
mammary tumour virus replication in vivo. Nature 2007, 445:927-30.
33. Okeoma CM, Shen M, Ross SR: A novel block to mouse mammary tumor
virus infection of lymphocytes in B10.BR mice. J Virol 2008, 82:1314-22.
34. Schliemann C, Roesli C, Kamada H, Borgia B, Fugmann T, Klapper W, Neri D:
In vivo biotinylation of the vasculature in B-cell lymphoma identifies
BST-2 as a target for antibody-based therapy. Blood 2010, 115:736-44.
35. Parks WP, Ransom JC, Young HA, Scolnick EM: Mammary tumor virus
induction by glucocorticoids Characterization of specific transcriptional
regulation. J Biol Chem 1975, 250:3330-6.
doi:10.1186/1742-4690-9-10
Cite this article as: Jones et al.: Bone marrow stromal cell antigen 2
(BST-2) restricts mouse mammary tumor virus (MMTV) replication in
vivo. Retrovirology 2012 9:10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jones et al. Retrovirology 2012, 9:10
http://www.retrovirology.com/content/9/1/10
Page 12 of 12